|Year : 2019 | Volume
| Issue : 1 | Page : 35-38
Invasive pulmonary Aspergillus infection in an immunocompetent host following severe dengue
S Bhavana Reddy, Sudha Vidyasagar, Nandakrishna Bhat, Muralidhar Varma
Department of Medicine, Kasturba Hospital, Manipal, Karnataka, India
|Date of Web Publication||6-Nov-2019|
Department of Medicine, Kasturba Hospital, Manipal, Karnataka
Source of Support: None, Conflict of Interest: None
Aspergillus species are widespread in the environment with Aspergillus fumigatus being the most common pulmonary pathogen. In a person with normal immunity, Aspergillosis in the lung can mainfest as hypersensitivity reaction. It can also present as an invasive infection in immunocompromised patients. In its severe form, invasive pulmonary aspergillosis (IPA) is commonly seen in severe immunodeficient individuals and is often fatal. We report a case of IPA in an immunocompetent patient following severe dengue fever who was successfully treated with voriconazole.
Keywords: Aspergillosis, dengue fever, immunocompetent host, severe dengue
|How to cite this article:|
Reddy S B, Vidyasagar S, Bhat N, Varma M. Invasive pulmonary Aspergillus infection in an immunocompetent host following severe dengue. J Clin Sci Res 2019;8:35-8
|How to cite this URL:|
Reddy S B, Vidyasagar S, Bhat N, Varma M. Invasive pulmonary Aspergillus infection in an immunocompetent host following severe dengue. J Clin Sci Res [serial online] 2019 [cited 2021 Oct 21];8:35-8. Available from: https://www.jcsr.co.in/text.asp?2019/8/1/35/270385
| Introduction|| |
Aspergillosisin the lung can mainfest as hypersensitivity reaction. It can also present as an invasive infection in immunocompromised patients. Invasive aspergillosis is a disease of immunocompromised host and is often rapidly fatal infection. This is characterised by invasion of blood vessels and lymphatics with multifocal infiltrates. Immunosuppression which predisposes to invasive disease is in the form of profound neutropenia, transplant recipient patients and patients of AIDS or chronic granulomatous disease. Here, we report a case of invasive pulmonary aspergillosis (IPA) in a host following severe dengue fever, without any apparent immunodeficient state.
| Case Report|| |
A 34-year-old female, resident of a village in Davanagere near a poultry farm, housewife, presented with high-grade fever, icterus and vomiting for the past 4 days. At presentation, she was conscious, oriented and afebrile. Icterus was present. Petechial rash was present on both lower limbs. There were no cyanosis, no clubbing and no lymphadenopathy. Pulse rate was 88 bpm, regular, blood pressure was 120/80 mmHg and B/L breath sounds was normal. Adventitious sounds-Rhonchi present. Examination of the abdomen and nervous, the cardiovascular system were normal. Investigations revealed: haemoglobin 11.9 g/dL, total leucocyte count 12,900/mm3, band forms 8%, lymphocytes 18% (reactive forms) and platelets 34,000/mm3. Erythrocyte sedimentation rate 21 mm/ at the end of the first hour. Quantitative buffy coat test for material parasite was negative. Random blood glucose was 231 mg/dL; glucosylated haemoglobin was 6%, total Bilirubin 8.1 mg/dL, aspartate aminotransferase 5432 IU/L, alanine aminotransferase 1809 IU/L, alkaline phosphatase 219 IU/L and serum albumin 3.1 g/dL. Chest radiograph was normal [Figure 1]a. She tested positive for NS1Ag and dengue immunoglobulin M by enzyme linked immunosorbent assay (ELISA). Testing for malaria, leptospira, scrub typhus, acute viral hepatitis A, B and E were negative. Working diagnosis of dengue fever with hepatic dysfunction was made and her blood counts and liver profile were monitored.
|Figure 1: Normal chest radiograph (postero-anterior view) (a). Chest radiograph (postero-anterior view) of the same patient showing right Upper zone consolidation|
Click here to view
With symptomatic treatment, her thrombocytopenia recovered and liver function tests normalized. During the hospital stay, she developed new-onset fever and cough with breathlessness. She was diagnosed with hospital-acquired pneumonia with sepsis, septic shock requiring inotropes and non-invasive ventilation. She was treated with injectable meropenem for Escherichia coli pneumonia and bacteremia as per se nsitivity for 14 days. Despite the improvement in haemodynamic status and hypoxia, she continued to be febrile with no resolution of consolidation [Figure 1]. Computed tomography of the thorax showed consolidation and cavitatory lesion in the left upper lobe and consolidation with ground glassing in the right upper lobe, few enlarged subcarinal lymph nodes [Figure 2]. Bronchoscopy showed fleshy mass in the right upper bronchus which on biopsy showed Aspergillus fumigatus [Figure 3].
|Figure 2: Contrast-enhanced computed tomography thorax [mediastinal window (a) lung window (b)] showing the right upper lobe necrotising pneumonia with cavity in the left upper lobe|
Click here to view
|Figure 3: Photomicrography showing Aspergillus fumigatus KOH mount ×40 magnification|
Click here to view
Serum galactomannan was positive. Bronchoalveolar lavage (BAL/fluid) tested positive for galctomannan antigen and showed growth of Aspergillus mould [Figure 4]. The patient, thus, had both histopathological and serological diagnosis of invasive aspergillosis. She was treated with intravenous (IV) Voriconazole after which she became afebrile and improved symptomatically and hence, later was changed to oral maintenance dose.
| Discussion|| |
Pulmonary aspergillosis is a collective term used to refer to a number of conditions caused by infection with a fungus of the Aspergillus species, usually A. fumigatus. Invasive aspergillosis is a disease of immunocompromised host and is often rapidly fatal infection. This is characterised by invasion of blood vessels and lymphatics with multifocal infiltrates. Histopathological examination with microbiological confirmation remains the gold standard in diagnosis. The isolation of Aspergillus spp. from BAL fluid from immunosuppressed patients is highly indicative of invasive aspergillosis (97% specificity), but is only positive in 50%–58% of patients.
Immunosuppression which predisposes to invasive disease is in the form of profound neutropenia, transplant recipient patients and patients of AIDS or chronic granulomatous disease. Invasive aspergillosis in immunocompetent hosts has been documented in the literature, and few case reports,, have been published. Natural immunity plays a major role in defence against aspergillosis. Risk factors for IPA in nonneutropenic patient are prolonged treatment with corticosteroids, chronic obstructive pulmonary disease, liver cirrhosis with prolonged intensive care units stay (>7 days) and broad-spectrum antibiotic use and liver failure. Immunoparalysis is sepsis with multiple organ dysfunction syndrome may also contribute to IPA.
In our patient, residence near poultry farm is a risk factor for exposure to Aspergillus mould. Sudden severe stress, associated hyperglycaemia and dengue fever induced severe hepatitis may have compromised immune barriers and led to the invasion of the vasculature and spread to lymph nodes. Further, prolonged hospital stay and broad-spectrum antibiotic use might also have contributed. Multitude of factors might have contributed to IPA in our patient. The patient responded to IV voriconazole, was afebrile and was continued on maintenance dose. High index of suspicion in critically ill patients will result in early diagnosis and treatment of IPA. Fungal infections following dengue fever are reported as isolated case reports.,
Treatment with IV voriconazole arrests the growth of Aspergillus. It is administered at a dose of 6 mg/kg q12 h for 2 doses, then 4 mg/kg q12 h IV for 5–7 days. Later, oral maintenance dose of 400 mg BD 2 doses, followed by 200 mg BD. Mean duration of treatment is 76 days.,
Informed consent was obtained from all the participants included in the study.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest 2002;121:1988-99.
Nguyen MH, Jaber R, Leather HL, Wingard JR, Staley B, Wheat LJ, et al
. Use of bronchoalveolar lavage to detect galactomannan for diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts. J Clin Microbiol 2007;45:2787-92.
Gupta S, Kakar A, Byotra SP, Prakash V. Invasive aspergillosis in an immunocompetent host. JK Sci 2004;6:103-5.
Fernandez-Hernandez S, Cortez AK, Varon J. Invasive pulmonary aspergillosis in an immunocompetent host. Crit Care 2015;18:43-5.
Mohammed AP, Dhunputh P, Chiluka R, Umakanth S. An unusual case of invasive aspergillosis in an immunocompetent individual. BMJ Case Rep 2015;2015. pii: bcr2015210381.
Hartemink KJ, Paul MA, Spijkstra JJ, Girbes AR, Polderman KH. Immunoparalysis as a cause for invasive aspergillosis? Intensive Care Med 2003;29:2068-71.
Sabino R, Faísca VM, Carolino E, Veríssimo C, Viegas C. Occupational exposure to Aspergillus
by swine and poultry farm workers in Portugal. J Toxicol Environ Health A 2012;75:1381-91.
Suzuki S, Kitazawa T, Ota Y, Okugawa S, Tsukada K, Nukui Y, et al.
Dengue hemorrhagic shock and disseminated candidiasis. Intern Med 2007;46:1043-6.
Kohli U, Sahu J, Lodha R, Agarwal N, Ray R. Invasive nosocomial aspergillosis associated with heart failure and complete heart block following recovery from dengue shock syndrome. Pediatr Crit Care Med 2007;8:389-91.
Greer ND. Voriconazole: The newest triazole antifungal agent. Proc (Bayl Univ Med Cent) 2003;16:241-8.
Driscoll TA, Yu LC, Frangoul H, Krance RA, Nemecek E, Blumer J, et al.
Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob Agents Chemother 2011;55:5770-9.
[Figure 1], [Figure 2], [Figure 3], [Figure 4]